AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18764946 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers Pure Points Programme
Number of subjects: 293
Study 18764946 — intervention group
Group type: EXPERIMENTAL
Intervention: Dr Atkins' New Diet Revolution
Number of subjects: 293
Study 18764946 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary Conley's 'Eat Yourself Slim' Diet & Fitness Plan
Number of subjects: 293
Study 18764946 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 293
Study 16562650 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy
Number of subjects: 0
Study 16562650 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiation therapy combined with chemotherapy
Number of subjects: 0
Study 12706932 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogen (CEE) (0.625 mg/day)
Number of subjects: 21
Study 12706932 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol (E(2)) (100 microg/day)
Number of subjects: 21
Study 12706932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10675209 — intervention group
Group type: EXPERIMENTAL
Intervention: New rapid diagnostic methods for TBM, details not available
Number of subjects: 0
Study 10675209 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for TBM, duration not specified
Number of subjects: 0
Study 10675209 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant corticosteroids for TBM, details not available
Number of subjects: 0
Study 9586515 — intervention group
Group type: EXPERIMENTAL
Intervention: Michigan splint therapy for two months
Number of subjects: 40
Study 9586515 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 40
Study 8246258 — intervention group
Group type: COMPARATOR
Intervention: E. coli O157 agglutinating antibodies
Number of subjects: 121
Study 8246258 — intervention group
Group type: COMPARATOR
Intervention: IgG antibodies against whole intact E. coli O157 cells
Number of subjects: 121
Study 8246258 — intervention group
Group type: COMPARATOR
Intervention: Faecal IgA specific for E. coli O157
Number of subjects: 121
Study 8246258 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up faecal samples
Number of subjects: 121
Study 3542383 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for breast cancer
Number of subjects: 113
Study 30545125 — intervention group
Group type: EXPERIMENTAL
Intervention: MyNutriCart app
Number of subjects: 51
Study 30545125 — intervention group
Group type: COMPARATOR
Intervention: Traditional group (face-to-face counseling)
Number of subjects: 51
Study 27354079 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training (CST) intervention with a survivorship planning consultation.
Number of subjects: 0
Study 27354079 — intervention group
Group type: COMPARATOR
Intervention: Control arm with time-controlled, manualised wellness rehabilitation consultation focused on healthy nutrition and exercise post-chemotherapy.
Number of subjects: 0
Study 27354079 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training (CST) intervention.
Number of subjects: 0
Study 24231668 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 39
Study 24231668 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 39
Study 23468100 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of alcohol, clamped at a steady-state breath alcohol (BrAC) concentration of 60 mg/dL
Number of subjects: 40
Study 23468100 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline infusion
Number of subjects: 40
Study 21543294 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 47
Study 21543294 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone plus n-3 polyunsaturated fatty acids
Number of subjects: 47
Study 18714627 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-based simulation
Number of subjects: 64
Study 18714627 — intervention group
Group type: COMPARATOR
Intervention: Conventional lectures
Number of subjects: 64
Study 16585985 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl aminolevulinate photodynamic therapy (160 mg/g cream applied for 3 h prior to illumination by non‐coherent red light at 570‐670 nm, light dose 75 J/cm2)
Number of subjects: 27
Study 16585985 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 27
Study 16585985 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl aminolevulinate photodynamic therapy
Number of subjects: 27
Study 12669898 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ASA treatment after ASA desensitization
Number of subjects: 38
Study 10896012 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat technique with 0 kg load
Number of subjects: 20
Study 10896012 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat technique with 1 kg load
Number of subjects: 20
Study 10896012 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat technique with 3 kg load
Number of subjects: 20
Study 10896012 — intervention group
Group type: COMPARATOR
Intervention: Stoop technique
Number of subjects: 20
Study 9138436 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 micrograms/kg Catapres)
Number of subjects: 0
Study 9138436 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (15 micrograms/kg Droleptan)
Number of subjects: 0
Study 9138436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1303336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 0.1 mg/kg orally at a single dose
Number of subjects: 166
Study 1303336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 0.2 mg/kg orally at a single dose
Number of subjects: 166
Study 1303336 — intervention group
Group type: COMPARATOR
Intervention: Pyrantel pamoate 10 mg/kg orally at a single dose
Number of subjects: 166
Study 3512031 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (heparin fragment) 5000 anti-factor Xa units once daily
Number of subjects: 432
Study 3512031 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-dose heparin 5000 units twice daily
Number of subjects: 432
Study 3512031 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (heparin fragment)
Number of subjects: 432
Study 3512031 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-dose heparin
Number of subjects: 432
Study 30089234 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the rVLPFC
Number of subjects: 96
Study 30089234 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 96
Study 27771800 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Power Overreaching Protocol (HPOR)
Number of subjects: 14
Study 27771800 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Overtraining Protocol (HIOT)
Number of subjects: 14
Study 24853888 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation from 1 to 9 months
Number of subjects: 0
Study 22367654 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 42
Study 22367654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20657084 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap debridement plus Bioplant HTR
Number of subjects: 5
Study 20657084 — intervention group
Group type: COMPARATOR
Intervention: Open debridement alone
Number of subjects: 5
Study 18499363 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric status (weight-for-age, height-for-age, mid-upper arm circumference, head circumference)
Number of subjects: 204
Study 18499363 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic status
Number of subjects: 204
Study 18499363 — intervention group
Group type: EXPERIMENTAL
Intervention: Kilifi Developmental Inventory (psychomotor functioning assessment)
Number of subjects: 204
Study 19444658 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1 - OPTIFREE EXPRESS MPDS (polyquaternium‐1 0.001% and myristamidopropyl dimethylamine 0.0005%)
Number of subjects: 111
Study 19444658 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1 - OPTIFREE EXPRESS MPDS
Number of subjects: 111
Study 19444658 — intervention group
Group type: COMPARATOR
Intervention: Regimen 2 - ReNu MultiPLUS MPS (polyhexamethylene biguanide 0.0001%)
Number of subjects: 111
Study 16381629 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 200 microg every 2 weeks
Number of subjects: 141
Study 16381629 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa 40,000 U weekly
Number of subjects: 141
Study 11502918 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day for 28 days, followed by 10 mg/day)
Number of subjects: 286
Study 11502918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 11502918 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 286
Study 9972057 — intervention group
Group type: EXPERIMENTAL
Intervention: Western blot analysis in patients with Lyme borreliosis
Number of subjects: 48
Study 9972057 — intervention group
Group type: COMPARATOR
Intervention: Western blot analysis in controls
Number of subjects: 48
Study 9972057 — intervention group
Group type: EXPERIMENTAL
Intervention: Western blot analysis in patients with erythema migrans and Lyme arthritis
Number of subjects: 48
Study 9972057 — intervention group
Group type: EXPERIMENTAL
Intervention: Western blot analysis in neuroborreliosis patients
Number of subjects: 48
Study 9972057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of Western blot results (IgM/IgG)
Number of subjects: 48
Study 8072708 — intervention group
Group type: EXPERIMENTAL
Intervention: mini‐tracheotomy postoperatively
Number of subjects: 20
Study 8072708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mini‐tracheotomy)
Number of subjects: 20
Study 3392552 — intervention group
Group type: EXPERIMENTAL
Intervention: r-metHuIFN-Con1 at 30 mcg/m2/day
Number of subjects: 21
Study 3392552 — intervention group
Group type: EXPERIMENTAL
Intervention: r-metHuIFN-Con1 at 45 mcg/m2/day
Number of subjects: 21
Study 3392552 — intervention group
Group type: EXPERIMENTAL
Intervention: r-metHuIFN-Con1
Number of subjects: 21
Study 30415602 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160
Study 30415602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17160
Study 29939055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative habituation across treatment
Number of subjects: 111
Study 29939055 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear activation, fear variability, and nonhabituation fear decreases
Number of subjects: 111
Study 29939055 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher peak fear during nonhabituation exposures
Number of subjects: 111
Study 27289566 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% decline in circulating tumor cell (CTC) count after treatment
Number of subjects: 486
Study 27289566 — intervention group
Group type: COMPARATOR
Intervention: Stable CTC count (<30% fall or <30% increase)
Number of subjects: 486
Study 27289566 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC declines
Number of subjects: 486
Study 27289566 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% CTC decline after treatment from an initial count ≥5 cells/7.5 ml
Number of subjects: 486
Study 24465958 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure intervention (informed about objective compliance monitoring)
Number of subjects: 64
Study 24465958 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder intervention (use of acoustical reminders)
Number of subjects: 64
Study 24465958 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective compliance
Number of subjects: 64
Study 22151005 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) hydrocortisone regimen (30 mg daily) for 2 weeks
Number of subjects: 10
Study 22151005 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose (LD) hydrocortisone regimen (17.5 mg daily) for 2 weeks
Number of subjects: 10
Study 22151005 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 10
Study 19152905 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapies (including injection, thermocoagulation, clips)
Number of subjects: 4261
Study 19152905 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection alone
Number of subjects: 4261
Study 19152905 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection followed by thermal therapy
Number of subjects: 4261
Study 19152905 — intervention group
Group type: EXPERIMENTAL
Intervention: Clips
Number of subjects: 4261
Study 19152905 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery or mortality
Number of subjects: 4261
Study 19152905 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 4261
Study 17573581 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan (doses not specified)
Number of subjects: 319
Study 17573581 — intervention group
Group type: COMPARATOR
Intervention: No intervention (placebo)
Number of subjects: 319
Study 17573581 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in serum sodium (1 mmol/l increase)
Number of subjects: 319
Study 16168813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiation with rhenium-188-filled balloon system (17.6 Gy in 1.0-mm tissue depth)
Number of subjects: 256
Study 16168813 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up of patients with dissections who had not undergone TVR
Number of subjects: 256
Study 11999905 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian after 15 days of placebo trial post-BZD withdrawal
Number of subjects: 19
Study 11999905 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 15 days post-BZD withdrawal
Number of subjects: 19
Study 11999905 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 19
Study 9951215 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 36
Study 9951215 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 8547730 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (2 inhalations 4 times daily)
Number of subjects: 10
Study 8547730 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 inhalations 4 times daily)
Number of subjects: 10
Study 2178398 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐ELS 8 oz per day
Number of subjects: 32
Study 2178398 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐ELS 16 oz per day
Number of subjects: 32
Study 2178398 — intervention group
Group type: COMPARATOR
Intervention: Placebo 8 oz per day
Number of subjects: 32
Study 2178398 — intervention group
Group type: COMPARATOR
Intervention: Placebo 16 oz per day
Number of subjects: 32
Study 375732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (Ancef), administered intravenously in a high-dose, short perioperative regimen
Number of subjects: 122
Study 375732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 375732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (Ancef)
Number of subjects: 122
Study 31498251 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based Korean Advanced Life Support (n = 30)
Number of subjects: 60
Study 31498251 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based education (n = 30)
Number of subjects: 60
Study 31100332 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental filling (IF) with etch-and-rinse (ER)
Number of subjects: 72
Study 31100332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-fill (BF) with etch-and-rinse (ER)
Number of subjects: 72
Study 31100332 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental filling (IF) with self-etch (SE)
Number of subjects: 72
Study 31100332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-fill (BF) with self-etch (SE)
Number of subjects: 72
Study 31100332 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance of BF technique
Number of subjects: 72
Study 31100332 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance with ER strategy
Number of subjects: 72
Study 27693404 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality associated with conventional physiotherapy
Number of subjects: 30
Study 27693404 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional physiotherapy only)
Number of subjects: 30
Study 26304900 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP care
Number of subjects: 221
Study 23392634 — intervention group
Group type: COMPARATOR
Intervention: Whole Brain Radiotherapy (WBRT) 20 Gy
Number of subjects: 113
Study 23392634 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiotherapy (WBRT) 30 Gy
Number of subjects: 113
Study 23392634 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 113
Study 21529775 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus clarithromycin (CLM) 500 mg b.i.d. for 3 days
Number of subjects: 40
Study 21529775 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus clarithromycin (CLM)
Number of subjects: 40
Study 21529775 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) plus placebo
Number of subjects: 40
Study 19122034 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 1.25 mg/day
Number of subjects: 281
Study 19122034 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 5.0 mg/day
Number of subjects: 281
Study 19122034 — intervention group
Group type: COMPARATOR
Intervention: Switch from placebo to FTY720
Number of subjects: 281
Study 19122034 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of FTY720 treatment
Number of subjects: 281
Study 19122034 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 (both doses) after 24 months
Number of subjects: 281
Study 19122034 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720
Number of subjects: 281
Study 17508683 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0
Study 17508683 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 0
Study 15138648 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive function
Number of subjects: 151
Study 15138648 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual and vestibular afferences
Number of subjects: 151
Study 12370700 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily pain management diary with nurse coaching regarding the pain management program
Number of subjects: 155
Study 12370700 — intervention group
Group type: COMPARATOR
Intervention: Daily pain management diary for data collection
Number of subjects: 155
Study 9874914 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced smoking abstinence (smoking ban during BMT)
Number of subjects: 10136
Study 7735515 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of a new, partially purified, characterized and standardized pollen extract of P. officinalis allergen (alum-absorbed depot preparation)
Number of subjects: 40
Study 2525985 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (200 mg twice a day)
Number of subjects: 0
Study 2525985 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg once a day)
Number of subjects: 0
Study 2525985 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (50 mg three times a day)
Number of subjects: 0
Study 2525985 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 0
Study 124195 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 6
Study 124195 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine
Number of subjects: 6
Study 124195 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 6
Study 124195 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (PGF2 alpha)
Number of subjects: 6
Study 124195 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2)
Number of subjects: 6
Study 31706638 — intervention group
Group type: EXPERIMENTAL
Intervention: RUL‐UB ECT combined with Venlafaxine
Number of subjects: 240
Study 31050763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) + Care as Usual (CAU)
Number of subjects: 70
Study 31050763 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 70
Study 28667080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (300,000 IU)
Number of subjects: 120
Study 28667080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation
Number of subjects: 120
Study 28667080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25586156 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 342
Study 25586156 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 342
Study 23607593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin for 12 weeks
Number of subjects: 408
Study 23607593 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 408
Study 23607593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin for 16 weeks
Number of subjects: 408
Study 21327911 — intervention group
Group type: EXPERIMENTAL
Intervention: Talniflumate (740 mg) with magnesium hydroxide (1 g)
Number of subjects: 0
Study 21327911 — intervention group
Group type: COMPARATOR
Intervention: Talniflumate (740 mg) without magnesium hydroxide
Number of subjects: 0
Study 19961638 — intervention group
Group type: EXPERIMENTAL
Intervention: Hallway 6-minute walk test
Number of subjects: 19
Study 19961638 — intervention group
Group type: COMPARATOR
Intervention: Treadmill 6-minute walk test
Number of subjects: 19
Study 17377400 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography
Number of subjects: 31
Study 17377400 — intervention group
Group type: COMPARATOR
Intervention: pH-monitoring
Number of subjects: 31
Study 15529259 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 3496